A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Hospital, Lille

About this trial

The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² \> BMI ≥ 30 kg/m²) with NASH complicated of advanced fibrosis (F3 and F4 fibrosis grade according to Brunt score).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provide written informed consent and agree to comply to the study protocol prior to enrolment.

For F3 fibrosis patients: 35>BMI≥ 30kg/m² ; Fibroscan ≥ 9kPa or FibrometreVM ≥0.526 predicting a F3 fibrosis score grade within 1 month before inclusion or F3 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.

For F4 fibrosis patients: 50>BMI≥ 30kg/m² ; Fibroscan ≥ 15kPa predicting a F4 fibrosis score grade within 1 month before inclusion or F4 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.

Fibroscan ≥ 9kPa or FibrometreVM ≥0.526 predicting a F3 or F4 fibrosis score grade within 1 month before inclusion Or F3 or F4 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.

Disqualifiers

Previous history of bariatric surgery (except gastric ring removed for more than 3 years).

Decompensated cirrhosis (MELD> 7 CPT score> 5, previous history of decompensation (encephalopathy, ascites, jaundice, varicose vein rupture)

Hepatocellular carcinoma

Platelets <125 000; TP <80%; bilirubin <20 mmol / l; albumin <35 g / L.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Lifestyle therapy

    Other intervention

    Lifestyle habits (caloric intake and exercise) + pedometer

  • Bariatric surgery

    Procedure/Surgery

    Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Bariatric surgeryExperimental treatment 1 intervention
Group B: Lifestyle therapyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Rate of disappearance of NASH without worsening of fibrosis grade

Diagnosis of NASH on the liver biopsy

Time frame
at 60 weeks after randomization

Secondary outcomes

1

Change in the NAS (Nafld Activity Score) score

NAS is a histological score established on the liver biopsy. The NAS ranges form 0 to 8. 8 is associated with the highest severity.

Time frame
at 60 weeks after randomization
2

Percentage of patients achieving at least a 2 point improvement in the NAS (≥2 points) without worsening of fibrosis grade

NAS established on the liver biopsy

Time frame
at 60 weeks after randomization
3

Change in the Brunt fibrosis score,

Brunt fibrosis is a histological score ranges from 0 to 4. The Brunt fibrosis score is established on the liver biopsy. It is the recommended score for the evaluation of fibrosis in NASH and NAFLD. On the scale, "0" is an absence of fibrosis, whereas "4" matches with cirrhosis.

Time frame
at 60 weeks after randomization
4

Change in the Metavir score

METAVIR fibrosis score is established on the liver biopsy. METAVIR fibrosis is a histological score ranges from 0 to 4. This score is more discriminant than the Brunt score for the severe form of fibrosis that are included in this study.On the scale, "0" is an absence of fibrosis, whereas "4" matches with cirrhosis.

Time frame
at 60 weeks after randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Lille

Lead sponsor

Ministry of Health, France

Collaborator